FY ending December 2026 – Q3 Financial Summary

Summary of Results

Oncolys BioPharma Inc.'s Q3 for the fiscal year ending December 2026 posted net sales of 527,808 thousand yen, operating loss of 1,104,482 thousand yen, ordinary loss of 1,112,040 thousand yen, and quarterly net loss of 1,115,090 thousand yen. Net sales rose substantially year-on-year, while losses continued to be incurred. Progress in domestic and international product launches and clinical development are notable. Earnings forecasts were not disclosed due to difficulty in making reasonable estimates; forward-looking information is explained in the attached materials. Research and development expenses totaled 972,693 thousand yen, and the company reported an R&D organization of 26 people. Exercise of stock acquisition rights resulted in increases in capital stock and capital surplus, causing changes in the capital structure.

Outlook and Capital Trends

With no earnings forecast published, significant uncertainty remains. Revenues may be affected by domestic and international sales and milestone income related to OBP-301, development events such as OBP-601, and domestic commercialization of Telomelysin injections. The supplementary information in the financial summary details R&D progress, organization and pipeline status, and attention should be paid to milestone and license agreements as potential revenue sources. Capital increases due to exercised stock acquisition rights have occurred, so dilution should be monitored.